UBS AG buy 8,825,000 6.7%

eSensor LAUNCHED!!!

FDA clearance for Cystic Fibrosis DNA Test

Sales of the eSensor instrument and CF test will commence in the first half of 2006 as planned.. . James White, CEO of Osmetech said: 'Gaining FDA clearance for our first microarray based test developed for our new eSensorTM molecular diagnostics instrument is a major step forward for our Molecular Diagnostics Division and will help to establish Osmetech as a key player in the fast growing moleculardiagnostics market. In addition, this FDA clearance helps to validate our microarray technology for routine use in the laboratory. Critical Care DivisionThe Division has a strong product portfolio and is well placed to continue the growth of instrument placements throughout the world, leading to revenues from proprietary consumables for a number of years to come.Sales of OPTI instruments and consumables remained strong resulting from increased sales of the new touchscreen version of the long-established OPTI (CCA). In 2006 we will start to see an important contribution to sales from the new OPTI LION portable electrolyte analyser and the OPTI R blood gas and electrolyte analyser with reusable consumable as these products are rolled out internationally.' Molecular Diagnostics DivisionFollowing FDA approval of the eSensorTM platform Osmetech are now looking to progress discussions with strategic partners who are looking for cost effective and easy to use instrumentation and consumables to work on other complex assays both in the healthcare and non healthcare markets. The next Osmetech Molecular test targeted for FDA submission will be the CYP 450 pharmacogenomics assay, which is currently in development. James White, CEO of Osmetech commented: 'We have been delighted with the rapid integration of the CMS business acquired in July. The powerful combination of the eSensor product together with OPTI GENE provides Osmetech Molecular Diagnostics with an excellent position in this rapidly developing and growing market sector. Both products remain on schedule for launch and revenue generation in the first half of 2006'

Sales to year end up over 40%

Osmetech has reported a strong rise in sales in the latter part of 2005 with growth driven byabove-forecast revenues at its Critical Care blood gas analysis division.. Sales for the Critical Care division in calendar year 2005 exceeded $14.7m, representing an increase of over 60% compared to the calendar year 2004. Approximately half of this overall growth is due to sales to veterinary distribution partner, IDEXX Laboratories, Inc.

Vetstat Exceeds Idexx Expectations

Sales of the VetStat electrolyte and blood gas analyser have been very encouraging and continue to exceed expectations. IDEXX's sales successes and continuing marketing efforts should result in further strong growth for the foreseeable future. As the installed base of instruments becomes established, revenues from proprietary consumables are expected to increase as a proportion of this veterinary business. Following a deal with leading US vetinary hopsital chain Banfield, Idexx are contracted to supply an additional 450 Vetstat devices over the coming year.Good progress is also being made with IDEXX on the development and supply contract to create a new platform for measuring critical care parameters based on Osmetech's proprietary optical fluorescence technology and consumables. It is anticipated that this market leading product is on target for launch late 2006/2007.

Critical Care Product Range - In Production

OPTI-CCA OPTI-LION OPTI-R OPTI-2L

Critical Care Consumable Product Range - In Production

SamplerCassette Callibration DataTrol

Molecular Diagnostics Product Range - In Production

Opti-GeneeSensorBiochipConsumableOPTI Tube Product Range - Licenced to Third Party

VetStat Cassettes OPTI Tube AVOX 4000

Buisness Partners

Major Shareholders

Organisation Shareholding % Gartmore 24,109,657 18.29% Schroder 18,874,284 14.32 UBS AG 8,825,000 6.70TD Waterhouse 7,011,137 5.32 Barclays Nom 6,638,092 5.04 Pershing Keen 5,870,773 4.45HSBC Global Nom 6,544,718 4.97 Roche 2,444,688 1.8 Marlborough UK Micro Cap Director Holdings James White 208,092 Gordon Hall 104,966 D Sandilands 61,597 GB Kuenster 33,054 A Marek 26,190 ADVFN Posters 5,896,564 4.5 Total Holdings 86,648,812 65.7%

Mouse Over Images For Product Data

If regular posters would like to be included in the ADVFN figure and if you are not bothered about the figures being public then post your long-term holding here.IE the number of shares you intend to keep for say more than 6 months?Alternatively if you'd rather keep your holdings secret but still want contribute to the overall figure then drop me a line to ditchpig@ntlworld.com

IDEXX now showing VETSTAT on their website. Also being exhibited at a load of conferences and vet type gatherings around the US and UK over the next few months. (see competitors OMH thread for more details and dates etc)

http://www.idexx.com/AnimalHealth/analyzers/vetstat/index.cfm

Extracted from an alternative OMH thread, a recent conversation with DS.

snorky2 - 31 Mar'05 - 18:32 - 4107 of 4124 moderate post | add to banned list


HOPE THIS HELPS:

1. Will there be a trading statement at year-end?

NO we dont do a yearend trading statement but any info or news will be announced
through normal channels.


2. Is development still happening on OPTI IV for ROCHE? Or has the ROCHE OMNI filled that gap?

NO its on the back boiler since buying company but could be used in the future. If
they intend to use it Roch will have the first choice of refusal

3. Are the new OPTI product launches still on track? or has the development of OptiGENE taken precedence?

No. The Optigene has not taken precedence. It is 2 sets of people bringing 2 bits to the market and yes the OPTI products are on track


4. Is IDEXX progressing as well as anticipated?

Yes very happy. It was displayed at the trade show in January and the reaction was
very good way ahead of what they expected it to be and the response on what they
regard as firm leads with people leaving details saying yes they are very
interested and they are in the process of making and shipping the product around
the world.



5. Are IDEXX buying large chunk of machines or are they buying to order for their customers.

They buy in bulk in anticipation of getting buyers to buy from them so no cash flow problems. Because they buy more units they get them at a discount to the health care market and sell them on around the world. He stated that the discounts were agreed because of the amount of units that they were likely to be selling. It is the same product as used in the health care but different software. Different badge but basically the same product. IDEXX have the chance to sell significantly more products to one customer and quoted simple clean business. With IDEXX funding all the advertising and sales staff all omh do is manufacture and sell to them.



6. How are sales progressing across the company compared with quoted expectations in
the reports.
The fall in figures explained in reports: But the sales will still show a significant improvement in the second half.
Sales going well and if sales were not going as planned they would be obliged to inform the market. SO very good.



7. Are their any new uses that the optigene can be used for apart from what has already been mentioned in report?

Very simple and fast for DNA analysis, Test for absence of a certain gene, Diagnose a
Disease, Searching for a foreign DNA, Sexually transmitted diseases: chlymidia,



8. What will the OptiGENE be used for first.

Will be used for the principle use of virginal infections market and make this a
priority and one or 2 more areas to applying the optigene. If there are Thrombosis
markers for genetics and someone is about to go for an operation it is important in
knowing how that persons blood will clot and recovery process after surgery, there
are certain genes associated with thrombosis and it can help with the assessment of
how the patient can recover from that operation.


9. What needs to be done before a test for chlamydia can be
marketed and how soon do you think it will be on the market.

Working with lgc who have a very good chemistry is highly sensitive and works very well with the optigene. Using tests to identify the chlymidia bacteria works very well with the omh device. There were able to demonstrate in tests in London the instrument worked very quickly and accurate in identifying chlymidia. Will be showed in November which is Europes biggest medical show and they will be showing a finished product and with a view to shipping that product in the first half of next year. IT will not be used initially for sexually transmitted diseases that will be probably follow a few months after that. He stressed that it is very simple to use, accurate and very quick. Then went on to stress the importance of diagnosing patients quickly for obvious reasons.




10. When was the last time a MARKET analyst visited the company

One just started in America to follow the company.



11. I think I heard someplace that you did a presentation to some
institutes if how did it go.

Yes impressed and waiting for finished product on the market then they would show further interest in the company. Once the product sells and profits show they will show further interest but explained they dont mind buying at a higher price once the share price is moving. He said he believes they are on course but is yet still to come.


12. Which Company do you think will give omh the most competition and is omh doing to
combat this.

Optigene, there are lots of competition out there but this has the benefit of being very cost effective, the price of the unit and will sell cheaper in bulk buys, simple to use, quick. They are cheaper than all competitors and no one can offer the same benefits of the optigene. He goes onto say that people will move away from the labs to using the optigene.


13. Why do you think the share price is as low as it is and what in your opinion?
would be a fairer value up to date.
Even he has given up on trying to work out why its so low. They are working on building value to the company and at some point people will suddenly notice what omh is doing and that will be reflected in the share price in time. They are setting milestones and hitting them.



14. I think I heard someplace that omh had a meeting with some institutions to get
them interested in the company. If so how did it go and who were these companies.




15. Are there any plans to employ or reduce staff from within the company?

No plans to recruit or bin staff



16. Do you think this bird flue will benefit OMH in anyway on future sales and if so
how?

No, not unless there is a massive increase in infections. But some sales have been generated but are small.

23.Acqisistions.

They will be looking to buy into products from other companies that will fit in with omh and its products and will be make in their own factory in USA if opertunity arises.

Looks like Osmo are becoming the new distributor of a portable blood gas analysis device the AVOX 4000 replacing Abbott Labs.
http://www.osmetech.com/products/avox/avoximeter4000.htm A good way to build the portfolio with very little risk involved.
I wonder if this is a prelude to a buyout?
Guess this was the deal MW as chuntering about?

I think this could be replacing a deal they had with Abbot Labs to sell it.
Hmmmm now who do we know at Osmetech who has an Abbot connection....

http://www.avoxsystems.com/news.shtml
SAN ANTONIO, Texas, January 1, 2004 - Avox Systems Inc., announced today that it has terminated its sales promotion agreement with Abbott Laboratories. Under the agreement that ended on December 31, 2003, Abbott had sold Avox's unique portable co-oximeter, the AVOXimeter 4000, in the U.S. and Canada. In the U.S., Avox continues to sell the AVOXimeter 4000 factory direct. In addition, a private-label version of the AVOXimeter 4000, the GEMOPLTM*, continues to be available from Instrumentation Laboratory of Lexington, MA. The GEM OPLTM is currently sold worldwide. Avox Systems is now seeking foreign and domestic distributors to market the AVOXimeter 4000. Additional information is available at the company's website, http://www.avoxsystems.com.


Better get this thread updated!!!

Great News!

RNS Number:5558L
Osmetech PLC
27 April 2005





News Release



27th April 2005



Osmetech plc licences vial technology to Roche Diagnostics


Osmetech plc ("Osmetech") announced today that the AIM-listed international
diagnostics group has licensed its proprietary plastic tube technology to Roche
Diagnostics, Mannheim Germany. This plastic tube technology was acquired as part
of Osmetech's purchase of Molecular Sensing plc.

The worldwide non-exclusive license will enable Roche to develop, manufacture
and sell plastic consumable vials for use on its large installed base of
LightCycler(R) instruments as an alternative to existing glass vials.

The same technology has been incorporated into consumables to be supplied for
use with Osmetech's Opti GENE instrument scheduled to be exhibited at Medica
later this year. The Opti GENE is a fast and easy to use PCR based platform for
DNA and RNA analysis.

The terms of the license include an upfront payment to Osmetech plus royalties
based upon a percentage of the value of end user sales.

James White, CEO, Osmetech plc said, 'We are delighted that the acquisition of
Molecular Sensing has given us this opportunity to create additional revenue
before Opti GENE comes to market. Whilst those revenues will initially be
modest, we are pleased to be strengthening our relationship further with Roche
Diagnostics, one of the world's leading healthcare diagnostics companies.'



Ends



For further information:


James White, David Sandilands
Osmetech plc 020 7849 6027



Matthew Moth
madano partnership 020 7378 7033

Looking Good

RNS Number:9019L
Osmetech PLC
05 May 2005

5th May 2005

Osmetech plc

Trading Update

The Company stated in the interim results announcement in January 2005 that the
second half of the financial year ended April 2005 should see a significant
overall sales increase both from the level achieved in the first half of the
current year and that achieved in the corresponding period last year.

As expected, that improved performance has now been achieved with sales in the
second half in US dollar terms:

* up 44% against H1 this financial year
* up 32% against H2 last financial year

Excluding the one off benefits recorded last year of SARs related sales in Asia
and initial distributor pipeline filling, underlying OPTI sales are up by over
10% in the last 12 months.

Total sales for the full year of approximately $10,863,000 were 4% ahead of last
year, although there will be a 9%-10% negative currency translation impact
compared to the prior year due to the relative weakness of the US dollar when
these dollar based sales are converted into sterling.

As anticipated, Osmetech has begun to see strong volumes flowing through its
OEM
manufacturing and supply agreement with IDEXX Laboratories, Inc. to provide a
customised OPTI CCA analyser, 'VetStat',
for veterinary markets.

The VetStat electrolyte and blood gas analyser was first exhibited by IDEXX in
January this year and is in the process of being rolled out around the world.
Initial interest has been very encouraging and IDEXX has already taken delivery
of a greater number of units than expected. On April 29th, at an investor
update, IDEXX announced that it has signed a major five year contract to supply
Banfield, the US's largest private veterinary practice operating from more than
450 locations, with a range of products, including an order for 'VetStat'
instruments.

Good progress is also being made with IDEXX on the development and supply
contract to create a new platform for measuring critical care parameters based
on Osmetech's proprietary optical
fluorescence technology. Both IDEXX contracts
are for a period of at least 10 years.

The new German sales office, Osmetech GmbH,
commenced trading at the start of
April and is now the exclusive distributor for OPTI products in this important
market. It has achieved a good first month of consumable sales to customers
operating the existing installed base of instruments. This direct sales
operation should improve the Group's ability to grow more aggressively in the
largest European healthcare market when the new OPTI and Opti GENE products are
launched.

Since the acquisition of Molecular Sensing plc ('MS') in October 2004, the
development of the Opti GENE genetic testing platform has continued on
schedule.
Osmetech plans to show the Opti GENE
instrument for the first time at the AMP
(US) and Medica (Europe) trade exhibitions in November this year with sales
likely to commence in the first half of 2006.

Osmetech has also licensed its proprietary tube technology, used in the Opti
GENE device and acquired during the acquisition of MS, to Roche Diagnostics. The
worldwide non-exclusive license will enable Roche to develop, manufacture and
sell plastic consumable vials for use on its large installed base of
LightCycler(R) instruments as an alternative to existing glass vials.

James White, Chief Executive, Osmetech plc said,

'As anticipated, the second half of our financial year has been strong with OPTI
sales hitting our targets.

'Looking ahead we expect continued strong growth through the IDEXX trading
relationship and an increased contribution from new OPTI products.

'We are delighted with the progress we have made following the MS acquisition.
In addition to the licensing agreement that we have signed with Roche
Diagnostics our Opti GENE instrument and assay development programme is on
track
to deliver a strong point of entry into the fast-growing genetic testing market.

'As well as exploiting the opportunities that we have within our existing
portfolio of healthcare diagnostics products, we will also continue to search
for other opportunities to grow the business and leverage our operations further
through appropriate acquisitions.'

The full year preliminary results for the year ended 30 April 2005 are expected
to be announced in July 2005.

Ends

For further information:

James White, David Sandilands
Osmetech plc 0207 378 7033

Matthew Moth
madano partnership 0207 378 7033

There have been several significant developments since I started this thread.
Osmetech are now selling the AVOXIMETER 4000 worldwide (- USA) in a deal with AVOX.
Roche have licensed the plastic tubing technology Osmetech acquired as part of their purchase of Molecular Sensing Ltd.
UTI would appear to be more or less dead though the BV e-nose may have some life left in it yet.
The deal with Idexx to supply OPTI-CCA machines as VETSTAT is progressing better than expected with IDEXX have landed a contract to supply a leading American national vetinary hospital chain. 450 additional VETSTAT machines are required to fulfil this deal.
The company have issued a trading update announcing sales are up 4% on last year and that they have now opened a sales department in Germany.
GENEDRIVE has been re-branded as OPTi-GENE and is to be displayed both here and in America in November and then there is the yet to be formally announced OPTI -LION, a device to measure electrolyte and pH analytes.

Better get my finger out and get this thread updated.

Looks like something is happening at last with OMH.
MMs 6v2 and some chunky trades going through.
Wonder if some news has leaked?

pth

would appear so

Lots of activity in OMH this morning and over the last few days. All started by this news:

Osmetech to buy CMS from Motorola, to raise 11 mln stg via placing
AFX


LONDON (AFX) - Healthcare diagnostics company Osmetech PLC said it is buying Clinical Micro Sensors Inc (CMS) from Motorola Inc to strengthen its position in genetic diagnostics testing.

Payment will be in the form of 78 mln warrants which Motorola can subscribe to at 1.75 pence.

In addition, Osmetech is raising 11 mln stg via a placing of shares at 1.75 pence to fund the working capital requirements of the enlarged group.

Osmetech said Motorola will invest 3.7 mln stg in the placing.

'CMS's diagnostic tests for cystic fibrosis and CYP450 are closest to commercial launch and we believe that these products have significant market potential,' said James White, Osmetech CEO.

Price got hammered on release, but mutterings of a Bid in the Zoo, and significant activity today, maybe worth a punt, DYOR etc etc.

pth

Bid rumours being mentioned as well.

mjr

that's what I said in the last line of my post!!

Keep up! LoL

pth

pth - I had a small amount of these and as part of a "dog clearing" exercise (similar to your own) ditched them recently and bought more DGT.

OMH may come good in several years time, it's always been jam tomorrow with them - so be prepared for a long wait to get any decent return.

Having said that watch them double in price now over the next two weeks just after I've sold lol !

og

This is one of the dogs I decided to keep and give them a bit of a chance. Don't really have much invested in financial terms and have probably thrown a bit more good money after bad today as have averaged down. So the dog has grown another tail! Very speculative now, particularly as they are doubling the amount of shares in issue with the CMS acquisition. You never know, if a Bid does transpire I might escape break even!

pth

By the way, two of my cleared out stubborn dogs have now started to show signs of life again. Amazing, isn't it?

Tipped as a speculative buy today by UK-Analyst.

This should ensure a mark-up Monday morning and plenty of buyers. If there is any overhang, this should help to clear it.

The article basically says that, with major companies ie Motorola having a big interest in OMH now, things may start to turn around.
Also results may show a good revenue from their previous acquisition that they have been keeping quiet about?

Looking good.

Yip, looks strong. Rising on decent volume, those panicking & selling on the placing RNS can now buy back for a healthy premium LOL. Roll on December when OPTIgene gets released!

Osmetech - Speculative buy at 1.875p
Says Bill Johnston, editor of WatsHot.com
Someone wrote to me a while back with intriguing questions about Osmetech (OMH). Was there a stalker seeking to manipulate the share price? To capture that elusive electronic nose just as it sniffed into life? The shares then stood at 2.9p. What was being suggested to him and others was that some individual or group was seeking systematically to create a dispirited ambience so as to allow the assets to change hands, just before a turning in the long trail of losses brought sudden prosperity to the company. I thought that share-price manipulation tended to be cruder, more obvious and shorter-term.

Well, if there is a stalker, he is certainly playing the long game, for he never appeared, the shares are now 1.875p. But what is Osmetech? And where will the next move be?

Former Official List tech-flop Osmetech (the company used to be called AromaScan) moved markets in 2002 and whilst new to AIM, bore many characteristic marks of a certain type of company already quoted there - that of the expensive pursuit of ground-breaking technology in search of those sunlit uplands where the product is in widespread demand and the money starts to pour in. Needless to say all it had done so far was pour out, and been enabled to do so by 17 million pounds in new monies raised in the preceding four years alone. That sum was supplemented by another 5 million pounds raised at 2p per share, an operation which accompanied a move to the alternative market.

When micro-organisms metabolise they emit volatile components that often have a characteristic smell. Osmetech's research had been concentrated on the development of sensors to detect these smells. That four-year period too only referred to the period when the board decided to concentrate on the application of its gas-sensing technology on the area of healthcare, and mostly on highly specific targets at that, eventually deciding to focus upon the diagnosis of urinary tract infections and related conditions; to good effect indeed, as FDA approval had been received in respect of one medical screening device. The company pointed out that the medical disciplines of obstetrics and gynaecology, STD clinics and surgical wards, to say nothing of primary care physicians and general practitioners, comprised the vast market at which the instruments are aimed - worth $100 million in the United States alone.

In order to provide the additional resources to fuel the business towards that longed-for destination of positive cash flow, the burn rate was to be reduced to 200,000 pounds per month, and the usual ritual sacrifice was duly conducted as four directors trudged from the boardroom, leaving the Chief Executive of three years, a former advisor of venture capitalists, a bit more space. His first major move was acquisition of OPTI, a blood-gas analysis business based in the United States but owned by Roche Diagnostics. This was early in 2003, and cost $3.5 million - but Roche put $1 million back into Osmetech for 4.5% of the enlarged equity. OPTI, with a 4,000-strong installation base, was expected to generate $7 million of sales in the 12 months following completion. The assertion was that its cash-generative characteristics would give a two-year payback. Just the same, in October of the same year 2 million pounds more was raised at 3p per share. The following year, September 2004 an all-paper bid in ordinary shares - 3.1 million pounds - was tabled in respect of the acquisition of OFEX-quoted Molecular Sensing PLC. Molecular Sensing develops tools utilising polymerase chain reaction techniques which are expected to be complementary to the expertise of Osmetech.

Interim sales to October 2004 were 2.4 million pounds against the 3.4 million pounds recorded for the previous year, this being partly due to an extraordinary spike in the previous year due to SARS in China, and partly to the weak dollar. The acquisition of Molecular Sensing had seen the cash in the enlarged balance sheet buttressed by almost 2 million pounds, to 3.6 million pounds; whilst the period had produced a 1 million pounds operating loss; and although much stronger trading was expected in the second half, any question of profit was scrupulously avoided. A trading update in May of this year told of sales in that second half (to April) 44% ahead and was grimly positive - but no more.

Then last week came another deal as the company agreed to acquire a US organisation, CMS, from Motorola. CMS is a developer of instruments in the field of genetic diagnostics testing. CMS cost Motorola $280 million ten years ago, when the giant was interested in electrochemical detection. Under the agreement Osmetech has acquired CMS free of debt and free of cash, and Motorola will retain responsibility for and will indemnify Osmetech in respect of other liabilities prior to completion. The consideration is unusual - the issue to Motorola of 78 million warrants at 1.75p per share. Not only that, but Motorola will invest 3.7 million pounds at the same 1.75p, and this will play a key part in an issue of 629 million shares in total to raise 11 million pounds in order to consolidate the new deal, and carry it forward. The two CMS tests which are nearest to market are for Cystic Fibrosis and a family of enzymes CYP450 the mutation of which impact how well individuals metabolise drugs. The enlarged group believes that the new technology is complementary to that of OPTI and gives a strong foothold in the fast-expanding genetic diagnostics market

The habit of making losses and seeking some means of funding them is ingrained in many hi-tech companies, and it looked as though it would take a mighty effort or a major event to add much allure to this company - however clever the technology. If OPTI is gambolling to good effect as expected, the financial benefits have been well concealed. It doesn't look as though Motorola's sally into the market has done its shareholders much good. However, with a couple of powerful giants now having an interest in Osmetech it might - just might - start to change. A speculative buy for the brave.

can anyone help explain this statement as i am a little confused as what this means as never heard of sub-divided shares ?

The first resolution proposed at the EGM was to sub-divide each Existing Share
into 1 ordinary share of 0.01p each and one Deferred Share. Now that this
resolution has been passed, subject to the completion of the Placing Agreement,
it is expected that dealings in the Existing Shares will cease at 4.30 p.m.
today, 25 July 2005 and dealings in Sub-Divided Ordinary Shares will commence
tomorrow, 26 July 2005.

For Shareholders holding their Existing Shares in uncertificated form, the
relevant CREST accounts will be credited with the Sub-Divided Ordinary Shares
tomorrow, 26 July 2005, in place of their Existing Shares. For Shareholders
holding their Existing Shares in certificated form, new share certificates will
not be issued in respect of the Sub-Divided Ordinary Shares,

I think its something to do with a consolidation they are planning later this year.

Consolidation?